相似文献
1
CCR 20th anniversary commentary: Preclinical study of proteasome inhibitor bortezomib in head and neck cancer.
Clin Cancer Res. 2015 Mar 1;21(5):942-3. doi: 10.1158/1078-0432.CCR-14-2550.
2
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Clin Cancer Res. 2001 May;7(5):1419-28.
3
The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Semin Oncol. 2001 Dec;28(6):626-33. doi: 10.1016/s0093-7754(01)90036-3.
4
Proteasome inhibition: a novel approach to cancer therapy.
Trends Mol Med. 2002;8(4 Suppl):S49-54. doi: 10.1016/s1471-4914(02)02315-8.
5
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
Cancer Treat Rev. 2003 May;29 Suppl 1:21-31. doi: 10.1016/s0305-7372(03)00079-3.
6
Cancer research. Taking garbage in, tossing cancer out?
Science. 2002 Jan 25;295(5555):612-3. doi: 10.1126/science.295.5555.612.
7
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Cancer Res. 2001 May 1;61(9):3535-40.
8
Potential for proteasome inhibition in the treatment of cancer.
Drug Discov Today. 2003 Apr 1;8(7):307-15. doi: 10.1016/s1359-6446(03)02647-3.
9
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Clin Cancer Res. 2003 Mar;9(3):1136-44.
10
Clinical update: proteasome inhibitors in solid tumors.
Cancer Treat Rev. 2003 May;29 Suppl 1:41-8. doi: 10.1016/s0305-7372(03)00082-3.
引用本文的文献
1
Induction and Regulation of the Immunoproteasome Subunit β5i (PSMB8) in Laryngeal and Hypopharyngeal Carcinoma Cells.
Med Sci Monit. 2020 Jul 7;26:e923621. doi: 10.12659/MSM.923621.
2
Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Int J Mol Sci. 2019 Oct 20;20(20):5194. doi: 10.3390/ijms20205194.
3
Targeting the unfolded protein response in head and neck and oral cavity cancers.
Exp Cell Res. 2019 Sep 1;382(1):111386. doi: 10.1016/j.yexcr.2019.04.007. Epub 2019 May 7.
4
Functional Genomics Approach Identifies Novel Signaling Regulators of TGFα Ectodomain Shedding.
Mol Cancer Res. 2018 Jan;16(1):147-161. doi: 10.1158/1541-7786.MCR-17-0140. Epub 2017 Oct 10.
本文引用的文献
1
Targeting the ubiquitin+proteasome system in solid tumors.
Semin Hematol. 2012 Jul;49(3):277-83. doi: 10.1053/j.seminhematol.2012.04.002.
2
The immunoproteasome as a target in hematologic malignancies.
Semin Hematol. 2012 Jul;49(3):258-62. doi: 10.1053/j.seminhematol.2012.04.003.
3
Targeting NF-κB in mouse models of lung adenocarcinoma.
Cancer Discov. 2011 Aug;1(3):200-2. doi: 10.1158/2159-8290.CD-11-0159.
4
NF-κB and the link between inflammation and cancer.
Immunol Rev. 2012 Mar;246(1):379-400. doi: 10.1111/j.1600-065X.2012.01099.x.
5
Bortezomib: understanding the mechanism of action.
Mol Cancer Ther. 2011 Nov;10(11):2029-30. doi: 10.1158/1535-7163.MCT-11-0745.
6
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.
Clin Cancer Res. 2011 Sep 1;17(17):5755-64. doi: 10.1158/1078-0432.CCR-11-0861. Epub 2011 Jul 12.
7
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Mol Cancer Ther. 2008 Jul;7(7):1949-60. doi: 10.1158/1535-7163.MCT-07-2046.
8
Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
Clin Cancer Res. 2008 Jul 1;14(13):4175-85. doi: 10.1158/1078-0432.CCR-07-4470.
9
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1400-12. doi: 10.1016/j.ijrobp.2005.05.007. Epub 2005 Jul 11.
10
Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Clin Cancer Res. 2001 May;7(5):1419-28.
Zotero 插件